title: Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbα antibodies.
abstract: Immune thrombocytopenia (ITP) is characterized by platelet clearance mediated primarily by autoantibodies against the platelet GPIIbIIIa and/or GPIbα. Steroid therapy is a first-line treatment for ITP. However, some patients are refractory to this therapy and currently no method can predict which patients will respond. To evaluate whether steroids are equally efficacious in treating patients with ITP caused by anti-GPIIbIIIa versus anti-GPIbα antibodies, we performed a retrospective study on 176 newly diagnosed patients with acute ITP who had severe bleeding symptoms and were admitted as resident patients to the hospital. The patients were treated first with intravenous administration of high-dose dexamethasone (DXM), followed by oral administration of prednisone. Response to therapy was observed in a majority of patients with antibodies specific for GPIIbIIIa (31/43) or without detectable antibodies against either GPIIbIIIa or GPIbα (36/45). In contrast, the steroid response was significantly lower in patients with anti-GPIbα antibodies (9/34) or with antibodies against both GPIbα and GPIIbIIIa (16/54). The preliminary findings of this study suggest that in future prospective clinical trials including corticosteroids, the anti-GPIbα, and -GPIIbIIIa status should be assessed in order to test its potential relevance in deciding future treatments.
authors.affiliation: Department of Hematology, The first affiliated hospital, Anhui Medical University, Hefei, China.
authors.forename: Qingshu
authors.initials: Q
authors.lastname: Zeng
authors.forename: Lingyan
authors.initials: L
authors.lastname: Zhu
authors.forename: Lili
authors.initials: L
authors.lastname: Tao
authors.forename: Jing
authors.initials: J
authors.lastname: Bao
authors.forename: Mingzhen
authors.initials: M
authors.lastname: Yang
authors.forename: Elisa K
authors.initials: EK
authors.lastname: Simpson
authors.forename: Conglei
authors.initials: C
authors.lastname: Li
authors.forename: Dianne E
authors.initials: DE
authors.lastname: van der Wal
authors.forename: Pingguo
authors.initials: P
authors.lastname: Chen
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Spring
authors.forename: Mingli
authors.initials: M
authors.lastname: Wang
authors.forename: Lingjie
authors.initials: L
authors.lastname: Zhang
authors.forename: Changgeng
authors.initials: C
authors.lastname: Ruan
authors.forename: Ming
authors.initials: M
authors.lastname: Hou
authors.forename: Ruixiang
authors.initials: R
authors.lastname: Xia
authors.forename: Heyu
authors.initials: H
authors.lastname: Ni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000276:immunology*; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000276:immunology*; D019038:Platelet Glycoprotein GPIb-IX Complex; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D005938:Glucocorticoids; D008562:Membrane Glycoproteins; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; C094990:adhesion receptor; D003907:Dexamethasone; D011241:Prednisone